Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,totalCurrentAssets,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IPIX,521000.0,418070016,2971000,,-6174000,,-6174000,468000,0,-3439000,-3439000,,-2735000,,,,0,0,3439000,0,-2735000,,-6174000,-6174000,2915000.0,114243000.0,8972000.0,3436000.0,1138000.0,22000.0,12408000.0,38000.0,-108591000.0,-2254000.0,1216000.0,8193000.0,6796000.0,8277000.0,1838000.0,496000.0,-183000,-40000,4165000,376000,1752000,941000,-577000,-3184000,94000,2703000,1481000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.11503379,0,PRE,PNK,False,False,0.287,1630526374,-0.0045000017,0.293,0.293,0.27,749678,31.888891,15,America/New_York,EDT,4,-1.5437398,0.27 - 0.293,0.2915,0.0,0.0,0,0,finmb_39474978,Other OTC,Innovation Pharmaceuticals Inc.,USD,1206996,790442,0.127,0.79375005,0.16 - 0.5,-0.213,-0.426,0.16,0.5,-0.032,-14400000,0.009,0.27942857,0.007571429,0.027096117,0.2573913,0.029608697,124475056,INNOVATION PHARMACEUTICALS INC,-0.43,,,0.5,0.16,0.2794,0.2574,1.21M,790.44k,418.07M,,367.72M,12.04%,0.02%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",0.00%,"-30,073.91%",-54.37%,,23k,0.00,,423k,-6.54M,-9.82M,-0.0320,,8.19M,0.02,3.86M,112.43,1.22,0.01,-7.42M,-6.44M,Value,01880,Healthcare,4,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",Wakefield,978 921 4125,MA,1609372800,United States,http://www.ipharminc.com,86400,301 Edgewater Place,Biotechnology,Suite 100
t-1,IPIX,1700000.0,418070016,524000,,-1173000,,-1173000,605000,0,-1129000,-1129000,,-44000,,,,0,0,1129000,0,-44000,,-1173000,-1173000,2969000.0,107290000.0,7022000.0,4669000.0,1318000.0,13000.0,11691000.0,35000.0,-102417000.0,-239000.0,1396000.0,7252000.0,6643000.0,7326000.0,,679000.0,122000,-3000,2758000,-626000,2851000,1234000,-93000,-1521000,94000,62000,683000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.11503379,0,PRE,PNK,False,False,0.287,1630526374,-0.0045000017,0.293,0.293,0.27,749678,31.888891,15,America/New_York,EDT,4,-1.5437398,0.27 - 0.293,0.2915,0.0,0.0,0,0,finmb_39474978,Other OTC,Innovation Pharmaceuticals Inc.,USD,1206996,790442,0.127,0.79375005,0.16 - 0.5,-0.213,-0.426,0.16,0.5,-0.032,-14400000,0.009,0.27942857,0.007571429,0.027096117,0.2573913,0.029608697,124475056,INNOVATION PHARMACEUTICALS INC,-0.43,,,0.5,0.16,0.2794,0.2574,1.21M,790.44k,418.07M,,367.72M,12.04%,0.02%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",0.00%,"-30,073.91%",-54.37%,,23k,0.00,,423k,-6.54M,-9.82M,-0.0320,,8.19M,0.02,3.86M,112.43,1.22,0.01,-7.42M,-6.44M,Value,01880,Healthcare,4,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",Wakefield,978 921 4125,MA,1609372800,United States,http://www.ipharminc.com,86400,301 Edgewater Place,Biotechnology,Suite 100
t-2,IPIX,-1598000.0,418070016,907000,,-1478000,,-1478000,540000,23000,-1424000,-1424000,,-54000,,,,0,23000,1447000,0,-54000,,-1478000,-1478000,3060000.0,102819000.0,7786000.0,1462000.0,,13000.0,9248000.0,33000.0,-101244000.0,-146000.0,78000.0,6018000.0,7369000.0,6110000.0,,557000.0,-277000,-34000,7099000,-286000,398000,5243000,-93000,-1822000,66000,153000,-1259000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.11503379,0,PRE,PNK,False,False,0.287,1630526374,-0.0045000017,0.293,0.293,0.27,749678,31.888891,15,America/New_York,EDT,4,-1.5437398,0.27 - 0.293,0.2915,0.0,0.0,0,0,finmb_39474978,Other OTC,Innovation Pharmaceuticals Inc.,USD,1206996,790442,0.127,0.79375005,0.16 - 0.5,-0.213,-0.426,0.16,0.5,-0.032,-14400000,0.009,0.27942857,0.007571429,0.027096117,0.2573913,0.029608697,124475056,INNOVATION PHARMACEUTICALS INC,-0.43,,,0.5,0.16,0.2794,0.2574,1.21M,790.44k,418.07M,,367.72M,12.04%,0.02%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",0.00%,"-30,073.91%",-54.37%,,23k,0.00,,423k,-6.54M,-9.82M,-0.0320,,8.19M,0.02,3.86M,112.43,1.22,0.01,-7.42M,-6.44M,Value,01880,Healthcare,4,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",Wakefield,978 921 4125,MA,1609372800,United States,http://www.ipharminc.com,86400,301 Edgewater Place,Biotechnology,Suite 100
t-3,IPIX,-7591000.0,418070016,276000,,-995000,,-995000,649000,0,-925000,-925000,,-70000,,,,0,0,925000,0,-70000,,-995000,-995000,3120000.0,95414000.0,8480000.0,-4471000.0,,,4009000.0,27000.0,-99766000.0,-146000.0,78000.0,775000.0,7826000.0,811000.0,200000.0,834000.0,35000,-12000,1490000,38000,1490000,588000,-93000,-890000,93000,-61000,-7015000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.11503379,0,PRE,PNK,False,False,0.287,1630526374,-0.0045000017,0.293,0.293,0.27,749678,31.888891,15,America/New_York,EDT,4,-1.5437398,0.27 - 0.293,0.2915,0.0,0.0,0,0,finmb_39474978,Other OTC,Innovation Pharmaceuticals Inc.,USD,1206996,790442,0.127,0.79375005,0.16 - 0.5,-0.213,-0.426,0.16,0.5,-0.032,-14400000,0.009,0.27942857,0.007571429,0.027096117,0.2573913,0.029608697,124475056,INNOVATION PHARMACEUTICALS INC,-0.43,,,0.5,0.16,0.2794,0.2574,1.21M,790.44k,418.07M,,367.72M,12.04%,0.02%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",0.00%,"-30,073.91%",-54.37%,,23k,0.00,,423k,-6.54M,-9.82M,-0.0320,,8.19M,0.02,3.86M,112.43,1.22,0.01,-7.42M,-6.44M,Value,01880,Healthcare,4,"Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",Wakefield,978 921 4125,MA,1609372800,United States,http://www.ipharminc.com,86400,301 Edgewater Place,Biotechnology,Suite 100
